Agios Pharmaceuticals (AGIO) EBIT (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly EBIT came in at -$110.6 million in Q2 2026, up 12.99% YoY from -$97.8 million in Q2 2025, and little changed on a QoQ basis from -$110.0 million in Q1 2026.
Agios Pharmaceuticals (AGIO) EBIT (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 15 years of EBIT data on file, last reported at -$110.6 million in Q2 2026.
- Quarterly EBIT rose 12.99% year-over-year to -$110.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$459.0 million (up 0.54% YoY) and the FY2025 annual result came in at -$472.1 million, down 10.9% from the prior year.
- EBIT steadied at -$110.6 million in Q2 2026, from -$110.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$90.6 million in Q1 2023 to a low of -$127.1 million in Q2 2025.
- A 5-year average of -$105.5 million and a median of -$104.3 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2025 — EBIT decreased 20.07% — and 2026, when it rose 12.99%.
- Tracing AGIO's EBIT over 5 years: stood at -$99.2 million in 2022, then dropped by 7.16% to -$106.3 million in 2023, then slipped by 17.65% to -$125.0 million in 2024, then advanced by 2.77% to -$121.6 million in 2025, then gained by 9.07% to -$110.6 million in 2026.
- The last three EBIT figures came in at -$110.6 million (Q2 2026), -$110.0 million (Q1 2026), and -$121.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Agios Pharmaceuticals | 2.00 Bn | 1.38 Bn | 41.75 Mn | -110.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -110.55 Mn |
| Mar 31, 2026 | -110.03 Mn |
| Dec 31, 2025 | -121.58 Mn |
| Sep 30, 2025 | -116.87 Mn |
| Jun 30, 2025 | -127.06 Mn |
| Mar 31, 2025 | -106.63 Mn |
| Dec 31, 2024 | -125.04 Mn |
| Sep 30, 2024 | -102.81 Mn |
| Jun 30, 2024 | -105.82 Mn |
| Mar 31, 2024 | -92.07 Mn |
| Dec 31, 2023 | -106.28 Mn |
| Sep 30, 2023 | -100.90 Mn |
| Jun 30, 2023 | -93.70 Mn |
| Mar 31, 2023 | -90.61 Mn |
| Dec 31, 2022 | -99.17 Mn |
| Sep 30, 2022 | -91.09 Mn |
| Jun 30, 2022 | -97.64 Mn |
| Mar 31, 2022 | -101.15 Mn |
| Dec 31, 2021 | -104.83 Mn |
| Sep 30, 2021 | -91.15 Mn |